Laboratory Testing for Enlarged Uterus with Heterogeneous Masses
Order CA-125, complete blood count (CBC), and consider CA 19-9 based on the CT findings showing heterogeneously enhancing soft tissue masses in an enlarged uterus, as these tests help differentiate benign fibroids from malignant transformation or other pathology.
Initial Laboratory Workup
The CT findings of an enlarged, globular uterus with heterogeneously enhancing masses and a cystic component require laboratory evaluation to assess for:
Essential Tests
CA-125: This is the most important tumor marker in this clinical scenario. Elevated CA-125 (>35 U/ml) was found in 67% of patients with malignant transformation of uterine masses 1. The NCCN guidelines specifically recommend CA-125 testing when extrauterine disease is suspected 2.
Complete Blood Count (CBC): Essential to assess for anemia from chronic bleeding and to evaluate white blood cell count, which helps distinguish inflammatory processes from malignancy. Leukocytosis can indicate infection or inflammatory conditions like actinomycosis 3.
CA 19-9: Consider ordering this marker, as 75% of patients with malignant transformation showed elevation (>37 U/ml) 1. This adds diagnostic value when combined with CA-125.
Additional Considerations
Squamous Cell Carcinoma (SCC) antigen: May be useful if there's concern for malignant transformation, particularly in mature cystic teratomas 1.
Alpha-fetoprotein (AFP): Consider if germ cell tumor is in the differential diagnosis 1.
C-reactive protein (CRP): Helpful if infectious/inflammatory etiology (such as actinomycosis) is suspected, especially with prolonged IUD use 3.
Clinical Context Matters
The imaging characteristics described—heterogeneously enhancing soft tissue masses with a cystic component—raise several diagnostic possibilities:
- Benign fibroids with degeneration (most common)
- Malignant transformation (requires exclusion)
- Adenomyosis with cystic changes
- Rare entities: teratoma, actinomycosis, or sarcoma
The combination of tumor markers with imaging findings significantly improves preoperative diagnostic accuracy 1. When CA-125 is elevated in conjunction with specific imaging features (masses >9.9 cm, obtuse angle of soft tissue components, irregular borders with enhancement), the likelihood of malignancy increases substantially.
Important Caveats
Normal tumor markers do not exclude malignancy 3. The definitive diagnosis requires histopathological examination.
Age matters: patients over 45 years with large masses (>9.9 cm) have higher risk of malignant transformation 1.
If tumor markers are elevated or clinical suspicion remains high, proceed directly to MRI pelvis for better tissue characterization before surgical planning 2, 4. MRI with diffusion-weighted imaging and ADC values can help distinguish fibroids from sarcomas with 98% sensitivity and 96% specificity 4.
The next step after laboratory testing should be endometrial sampling (biopsy or D&C) if there's any concern for endometrial pathology, as recommended by NCCN guidelines 2.